Similarly, mTOR inhibition in TSC patients has shown improvements for epileptic symptoms (Mizuguchi et al., 2019) but not for ASD-associated behaviors (Overwater et al., 2019), suggesting that treatment must be given in the critical period or that mTOR signaling is less important in ASC symptoms in humans. The gene discussed is MTOR; the disease is tuberous sclerosis.